1 results match your criteria: "CNPE Kyiv City Center of Nephrology and Dialysis[Affiliation]"
Article Synopsis
- The study aimed to evaluate the impact of the calcimimetic Etelcalcetide on secondary hyperparathyroidism in end-stage renal disease patients undergoing hemodialysis, comparing its effects to those in patients not treated with calcimimetics.
- A total of 203 patients were included, with 71 receiving Etelcalcetide and 132 in a historical control group, and results measured included changes in serum levels of parathyroid hormone, calcium, and phosphorus over 12 months, focusing on mortality and cardiovascular events.
- Results showed significant decreases in parathyroid hormone levels and cardiovascular event rates in the Etelcalcetide group compared to the historical group, suggesting a notable benefit of the treatment in reducing complications associated